Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,321)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01356628 | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | completed | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06156748 | CT Imaging for Guiding PA-TACE for HCC | completed | — | 1,770 | Zhujiang HospitalOTHER | 1 | Jul 28, 2025 |
| NCT01506973 | A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 119 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02030860 | A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | completed | Phase 1 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04508725 | Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC) | completed | N/A | 22 | Stanford UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04627064 | ABEMA Alone or in COMBO With MK-6482 | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05173103 | Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer(HERMIONE-13) | completed | — | 254 | University of Milano BicoccaOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03654547 | Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer | completed | Phase 1 | 48 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 2 | Jul 24, 2025 | clinicaltrials |
| NCT04069468 | Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)(PROACTIF) | completed | — | 1,247 | Boston Scientific CorporationINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03755141 | Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer | completed | Phase 2 | 109 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05632848 | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT01781728 | Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma | completed | Phase 2 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05892926 | HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia | completed | — | 204 | AstraZenecaINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07075562 | TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion | completed | N/A | 180 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05078775 | Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer | completed | N/A | 39 | Faeth TherapeuticsINDUSTRY | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06355024 | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | completed | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07066644 | Intraoperative Pathologic Evaluation of Central Lymph Nodes in Papillary Thyroid Carcinoma | completed | — | 509 | Seoul National University HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03963739 | Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer(PCW) | completed | — | 255 | Wake Forest University Health SciencesOTHER | 2 | Jul 16, 2025 | clinicaltrials |
| NCT02312817 | RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System | completed | N/A | 1,800 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT03117309 | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 164 | Michael B. Atkins, MDOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT01840306 | Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer | completed | — | 330 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06833268 | Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan | completed | — | 228 | Daiichi SankyoINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07053202 | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma | completed | N/A | 140 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT00832429 | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06314971 | Predicting Local and Distant Recurrence in T1 Colorectal Cancer(T1CR) | completed | — | 138 | City of Hope Medical CenterOTHER | 3 | Jul 3, 2025 | clinicaltrials |
| NCT06481397 | OSCAR I STUDY - The ONCObind CTC Removal Study | completed | N/A | 5 | ExThera Medical CorporationINDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02723331 | Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates | completed | Phase 2 | 48 | Academic Thoracic Oncology Medical Investigators ConsortiumINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03592888 | DC Vaccine in Pancreatic Cancer | completed | Phase 1 | 29 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07030842 | Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma | completed | — | 579 | Tongji HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06030180 | CLUE: CLinical Utility Study of EsoGuard(PR-0410) | completed | N/A | 566 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT06414304 | Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy(BLOOMSI) | completed | — | 30 | OncoAtlas LLCINDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03094052 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | completed | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05635279 | Effect of Nutritional Indices on the Prognosis of HCC Patients | completed | — | 150 | Juan KangOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04420598 | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease(DEBBRAH) | completed | Phase 2 | 41 | MedSIROTHER | 2 | Jun 24, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT04400474 | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study(CABATEN) | completed | Phase 2 | 93 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT02368886 | Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 123 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT04400656 | PROState Pathway Embedded Comparative Trial(IP3-PROSPECT) | completed | — | 139 | Imperial College LondonOTHER | 1 | Jun 18, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jul 28, 2025source: clinicaltrials